$OMER

Cable Thomas J. sold $87K of OMER

Cable Thomas J. sold 7,500 shares of OMEROS CORP (OMER) at $11.61 on 2026-05-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cable Thomas J.
Published May 27, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 8:37 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OMER
Neutral
high confidence
Mentioned
$OMER
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMERNeutralLow
01

Why it matters

The disclosure provides transparency on director selling activity but does not introduce new information about OMEROS operations, financial performance, or external catalysts.

02

Market read

This is primarily a sentiment/positioning datapoint for OMER, with limited fundamental implications.

03

What to watch

Traders may overreact to insider selling; the key missing detail is whether there were concurrent buys or other insider activity around the same period.

Relevance 2/10Novelty 3/10Timing: Filed 2026-05-27, transaction dated 2026-05-22.

Background

The article is an SEC Form 4 insider transaction disclosure for OMEROS Corp.

Company-level read

Ticker impact

$OMERNeutralHigh confidence
Context

OMEROS director Cable Thomas J. sold 7,500 shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a routine Form 4 insider transaction with a stated 10b5-1 plan, and it does not include new company fundamentals, guidance, or regulatory/contract events.

Market effects

No clear sector read-through from a single director 10b5-1 sale.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • OMEROS CORP

    Company whose director insider sale is disclosed on Form 4.

  • Cable Thomas J.

    Director who sold 7,500 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AZNMedAI 8/10

CHMP October decisions: AstraZeneca pulls prostate cancer filing; Orphelia gets a second chance; Ascendis nears EU launch

AstraZeneca withdrew its EU application for Truqap in prostate cancer. Orphelia Pharma gained CHMP backing for Kizfizo in glioblastoma. Ascendis Pharma neared EU approval for Yuviwel in achondroplasia. Sobi expanded Tryngolza's use to severe hypertriglyceridemia. Pfizer withdrew Ibrance's EU expansion. Revolution Medicines got CHMP backing for Rasonque in pancreatic cancer. Omeros failed to overturn Yartemlea's EU rejection. Lilly advanced Foundayo for obesity and diabetes in Europe.

$OMERHighAI 8/10

Why is Omeros stock sliding today?

Omeros (OMER) stock fell 5.4% in pre-market trading after the European Medicines Agency's committee issued a second negative opinion on its Yartemlea drug application. The company will end its European compassionate-use program and abandon plans to license EU commercialization rights. Insiders sold $3M in shares over the past year. The stock traded at $17.77, down from $18.79. The U.S. launch of Yartemlea remains on track, with next earnings expected in mid-November.